Form 8-K · Current Report · Filed 2026-05-01
Moderna Reports First Quarter 2026 Financial Results and Business Updates
Moderna, Inc. reported its first quarter 2026 financial results, showing total revenue of $389 million, a GAAP net loss of $(1.3) billion, and GAAP EPS of $(3.40). The company reiterated its plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. Moderna also provided updates on its pipeline, including regulatory milestones for its infectious disease portfolio and the initiation of a Phase 3 clinical study for its oncology therapeutics.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-26-000057
- CIK
- 0001682852
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$45.94
Next session
+3.0%
Since filing
+19.3%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, MRNA insiders reported 59 Form 4 transactions — net selling of $4.6M.
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.